{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.5","value":"0.1"},{"groupId":"OG001","spread":"0.6","value":"0.1"}]}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"0.0"},{"groupId":"OG001","spread":"0.7","value":"0.0"}]}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"-0.3"},{"groupId":"OG001","spread":"0.9","value":"-0.1"}]}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"-0.4"},{"groupId":"OG001","spread":"1.0","value":"-0.2"}]}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"-2.3"},{"groupId":"OG001","spread":"2.0","value":"-1.9"}]}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"-2.7"},{"groupId":"OG001","spread":"2.1","value":"-2.3"}]}],"title":"Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"-2.9"},{"groupId":"OG001","spread":"2.1","value":"-2.5"}]}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"518"}],"units":"Participants"}],"description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. A positive change indicates a worsening and a negative change is an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The intent-to-treat (ITT) population includes all participants who were randomized reporting a clinical score. Missing values were imputed using Last Observation Carried Forward.","reportingStatus":"POSTED","timeFrame":"Day 1, 3, 5, 8, 11, 15, 22, and 29","title":"Mean Change in the Ordinal Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}